Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

1.

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR; PROWESS Investigators.

Crit Care Med. 2003 Jan;31(1):12-9.

PMID:
12544987
[PubMed - indexed for MEDLINE]
2.

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.

Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL.

Crit Care. 2003 Apr;7(2):155-63. Epub 2003 Feb 28. Review.

PMID:
12720562
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.

McCoy C.

Expert Opin Drug Saf. 2004 Nov;3(6):625-37. Review.

PMID:
15500421
[PubMed - indexed for MEDLINE]
4.

Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated).

Rudis MI, Fish DN.

Pharmacotherapy. 2002 Dec;22(12 Pt 2):182S-195S. Review.

PMID:
12492225
[PubMed - indexed for MEDLINE]
5.

Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.

Frampton JE, Foster RH.

Pharmacoeconomics. 2004;22(7):445-76. Review.

PMID:
15137883
[PubMed - indexed for MEDLINE]
6.

Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis.

Bernard GR.

Crit Care Med. 2003 Jan;31(1 Suppl):S85-93. Review.

PMID:
12544981
[PubMed - indexed for MEDLINE]
7.

Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.

Barie PS, Hydo LJ, Shou J, Eachempati SR.

Surg Infect (Larchmt). 2006;7 Suppl 2:S77-80. Review.

PMID:
16895513
[PubMed - indexed for MEDLINE]
8.

Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.

McCoy C, Matthews SJ.

Clin Ther. 2003 Feb;25(2):396-421. Review.

PMID:
12749504
[PubMed - indexed for MEDLINE]
9.

Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis.

Kanji S, Devlin JW, Piekos KA, Racine E.

Pharmacotherapy. 2001 Nov;21(11):1389-402. Review.

PMID:
11714212
[PubMed - indexed for MEDLINE]
10.

Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated).

Morris PE, Light RB, Garber GE.

Am J Surg. 2002 Dec;184(6A Suppl):S19-24. Review.

PMID:
12521614
[PubMed - indexed for MEDLINE]
11.

[Identification of surgical patients for therapy with activated Drotrecogin alfa].

Utzolino S, Baier P, Hopt UT.

Anaesthesist. 2006 Jun;55 Suppl 1:30-5. Review. German.

PMID:
16607516
[PubMed - indexed for MEDLINE]
12.

Use of drotrecogin alfa (activated) in older patients with severe sepsis.

Alexander SL, Ernst FR.

Pharmacotherapy. 2006 Apr;26(4):533-8. Review.

PMID:
16553513
[PubMed - indexed for MEDLINE]
13.

Clinical trials in severe sepsis with drotrecogin alfa (activated).

Laterre PF.

Crit Care. 2007;11 Suppl 5:S5. doi: 10.1186/cc6156. Review.

PMID:
18269692
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated).

Short MA, Schlichting D, Qualy RL.

Curr Med Res Opin. 2006 Dec;22(12):2525-40. Review.

PMID:
17265595
[PubMed - indexed for MEDLINE]
15.

Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.

De Backer D.

Drug Saf. 2007;30(11):995-1010. Review.

PMID:
17973539
[PubMed - indexed for MEDLINE]
16.

New additions to the intensive care armamentarium.

Rice TW, Bernard GR.

Drugs Today (Barc). 2004 Feb;40(2):157-70. Review.

PMID:
15045037
[PubMed - indexed for MEDLINE]
17.

Risk-benefit analysis for drotrecogin alfa (activated).

Schein RM, Kinasewitz GT.

Am J Surg. 2002 Dec;184(6A Suppl):S25-38. Review.

PMID:
12521615
[PubMed - indexed for MEDLINE]
18.

Drotrecogin alpha (activated): the treatment for severe sepsis?

Vincent JL.

Expert Opin Biol Ther. 2007 Nov;7(11):1763-77. Review.

PMID:
17961098
[PubMed - indexed for MEDLINE]
19.

Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.

Green C, Dinnes J, Takeda AL, Cuthbertson BH.

Int J Technol Assess Health Care. 2006 Winter;22(1):90-100. Review.

PMID:
16673685
[PubMed - indexed for MEDLINE]
20.

Pharmacokinetics and clinical use of drotrecogin alfa (activated) in patients with severe sepsis.

Olsen KM, Martin SJ.

Pharmacotherapy. 2002 Dec;22(12 Pt 2):196S-205S. Review.

PMID:
12492226
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk